Literature DB >> 12515561

Ischaemic preconditioning and outcomes after angioplasty: effects of drug therapy.

Toru Kato1, Nobuo Yoshimoto.   

Abstract

Ischaemic preconditioning is one of the mechanisms by which human myocardium and human life are protected from ischaemic insults. One of the clinical situations in which we can discuss preconditioning is repetitive coronary occlusions by balloon inflation during elective percutaneous transluminal coronary angioplasty (PTCA) for stable angina pectoris. The severity of myocardial ischaemia assessed by ST-segment elevation or chest pain is less during the second balloon inflation compared with the first, if the duration of the first coronary occlusion is sufficient to precondition the myocardium. Many drugs have been identified that produce a reduction or induction in indices of preconditioning during PTCA. Preconditioning-mimetic drugs include adenosine, bradykinin, nitroglycerin and nicorandil. It is of paramount importance that we investigate and develop preconditioning-mimetic drugs which may enable an increased tolerance to effort angina, limit infarction size in susceptible patients, and decrease the incidence of sudden cardiac death as a result of ventricular tachyarrhythmias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12515561     DOI: 10.2165/00003495-200363020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  35 in total

1.  Preconditioning of human myocardium with adenosine during coronary angioplasty.

Authors:  M A Leesar; M Stoddard; M Ahmed; J Broadbent; R Bolli
Journal:  Circulation       Date:  1997-06-03       Impact factor: 29.690

2.  No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine.

Authors:  D R Wallbridge; R Schulz; C Braun; H Post; G Heusch
Journal:  J Mol Cell Cardiol       Date:  1996-08       Impact factor: 5.000

Review 3.  A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection?

Authors:  D M Yellon; G F Baxter
Journal:  J Mol Cell Cardiol       Date:  1995-04       Impact factor: 5.000

4.  Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.

Authors:  E Deutsch; M Berger; W G Kussmaul; J W Hirshfeld; H C Herrmann; W K Laskey
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

5.  Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty.

Authors:  T Kato; T Kamiyama; Y Maruyama; S Tanaka; N Yoshimoto
Journal:  Am Heart J       Date:  2001-06       Impact factor: 4.749

6.  Effects of naloxone on myocardial ischemic preconditioning in humans.

Authors:  F Tomai; F Crea; A Gaspardone; F Versaci; A S Ghini; C Ferri; G Desideri; L Chiariello; P A Gioffré
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

7.  Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease.

Authors:  T Matsubara; S Minatoguchi; H Matsuo; K Hayakawa; T Segawa; Y Matsuno; S Watanabe; M Arai; Y Uno; M Kawasaki; T Noda; G Takemura; K Nishigaki; H Fujiwara
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

8.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

9.  Phentolamine prevents adaptation to ischemia during coronary angioplasty: role of alpha-adrenergic receptors in ischemic preconditioning.

Authors:  F Tomai; F Crea; A Gaspardone; F Versaci; A S Ghini; R De Paulis; L Chiariello; P A Gioffrè
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

10.  Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

Authors:  F Tomai; F Crea; A Gaspardone; F Versaci; R De Paulis; A Penta de Peppo; L Chiariello; P A Gioffrè
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

View more
  1 in total

Review 1.  Advancing stem cell therapy from bench to bedside: lessons from drug therapies.

Authors:  Thekkeparambil Chandrabose Srijaya; Thamil Selvee Ramasamy; Noor Hayaty Abu Kasim
Journal:  J Transl Med       Date:  2014-09-04       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.